[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631182":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":56,"slug":26,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"IRCCS Centro San Giovanni di Dio Fatebenefratelli","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"L-serine group","EXPERIMENTAL","L-serine supplementation, 6 g\u002Fday, oral stick, 48 weeks.",[13],"Dietary Supplement: L-serine supplementation",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Maltodextrine supplementation, 6 g\u002Fday, oral stick, 48 weeks.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","L-serine supplementation","Participants randomized to the experimental arm will receive L-serine supplementation (6 g\u002Fday), administered orally as a single stick per day for a total duration of 48 weeks.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Participants randomized to the Placebo arm will receive Maltodextrine supplementation (6 g\u002Fday), administered orally as a single stick per day for a total duration of 48 weeks.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Moira Marizzoni, PhD","CONTACT","(+39) 030 35 01 563","mmarizzoni@fatebenefratelli.eu",[38],{"facility":5,"status":39,"city":40,"state":26,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Brescia","25125","Italy",{"type":44,"coordinates":45},"Point",[46,47],10.21472,45.53558,{"lat":47,"lon":46},[50],{"name":51,"role":34,"phone":52,"phoneExt":26,"email":53},"Annamaria Cattaneo, PhD","0303501598","acattaneo@fatebenefratelli.eu",{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100631182",false,"NCT07497347","Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing","Translational Investigation of Specific Amino Acid Supplementation and Lifestyle Factors in Brain Ageing","AAAgeing","Inclusion Criteria:\n\n* Age 65-85 years;\n* Presence of depressive symptoms, defined as a score ≥ 5 on the Geriatric Depression Scale-15 items (GDS-15) or ≥ 5 on the Patient Health Questionnaire-9 (PHQ-9).\n\nExclusion Criteria:\n\n* Diagnosis of dementia;\n* Use of antibiotics or anti-inflammatory medications within the previous 8 weeks;\n* Active gastrointestinal disease;\n* Severe chronic medical conditions (e.g., advanced-stage cancer, severe cardiac or renal disorders, or other debilitating diseases);\n* Renal dysfunction;\n* Current alcohol or substance abuse;\n* Major surgical procedures within the previous 6 months.","ALL","65 Years","85 Years",{"count":67,"type":68},84,"ESTIMATED","INTERVENTIONAL",[71],"NA","The aim of this clinical trial is to investigate the effects of L-serine supplementation on cognitive decline and psychosocial functioning in older adults with late-life depression (LLD). The study will evaluate changes in depressive symptoms, neural and cognitive functioning, and will assess neurophysiological, metagenomic, and biochemical alterations associated with L-serine supplementation compared with placebo.\n\nThe main research questions are:\n\n* Does L-serine supplementation affect cognitive function, depressive symptoms, and neural functioning in individuals with late-life depression?\n* What biological mechanisms may underlie the effects of L-serine on cognitive decline? Participants will be randomly assigned to one of two study arms: an intervention group (total n = 42) receiving L-serine at a dose of 6 g\u002Fday for 48 weeks, and a placebo group (total n = 42) receiving 6 g\u002Fday of maltodextrin for the same duration.\n\nAll participants will be assessed at three time points: T0 (baseline, prior to trial initiation), T18 (after 18 weeks), and T48 (after 48 weeks, at the end of the trial).\n\nAt each assessment, participants will:\n\n* complete clinical questionnaires and a neuropsychological assessment;\n* provide blood, fecal, and urine samples;\n* undergo electroencephalographic (EEG) recordings.",[74],"Late-Life Depression",[76,23,77],"Late-life depression","Ageing- related Cognitive Decline","2026-03-24",{"date":80,"type":81},"2026-03-27","ACTUAL",{"date":83,"type":81},"2026-03-01",{"date":85,"type":68},"2029-02-01",{"name":5,"class":6},1]